Amgen Inc. Payments to Acquire Available-for-sale Securities
Amgen Inc. (AMGN) reported Payments to Acquire Available-for-sale Securities of $2.73 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-04-25
- Amgen Inc. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $2.73B, a 61.40% decline year-over-year.
- Amgen Inc. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $6.95B, a 28.34% increase year-over-year.
- Amgen Inc. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $7.42B, a 3.84% decline year-over-year.
- Amgen Inc. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $12.17B, a 90.88% increase year-over-year.
- Amgen Inc. payments to acquire available-for-sale securities for fiscal 2017 was $33.61B, a 19.62% increase from fiscal 2016.
- Amgen Inc. payments to acquire available-for-sale securities for fiscal 2016 was $28.09B, a 8.15% increase from fiscal 2015.
- Amgen Inc. payments to acquire available-for-sale securities for fiscal 2015 was $25.98B, a 0.38% increase from fiscal 2014.
- Amgen Inc. payments to acquire available-for-sale securities for fiscal 2014 was $25.88B.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-03-31 | $2.73B 10-Q · filed 2018-04-25 | $9.68B derived: sum of 2 quarters · filed 2018-04-25 | $17.09B derived: sum of 3 quarters · filed 2018-04-25 | $29.26B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-12-31 | $6.95B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $14.36B derived: sum of 2 quarters · filed 2018-02-13 | $26.53B derived: sum of 3 quarters · filed 2018-02-13 | $33.61B 10-K · filed 2018-02-13 |
| 2017-09-30 | $7.42B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $19.58B derived: sum of 2 quarters · filed 2017-10-26 | $26.66B 10-Q · filed 2017-10-26 | $32.07B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-06-30 | $12.17B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-26 | $19.24B 10-Q · filed 2017-07-26 | $24.66B derived: sum of 3 quarters · filed 2018-04-25 | $32.37B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-03-31 | $7.08B 10-Q · filed 2018-04-25 | $12.49B derived: sum of 2 quarters · filed 2018-04-25 | $20.20B derived: sum of 3 quarters · filed 2018-04-25 | $26.58B derived: sum of 4 quarters · filed 2018-04-25 |
| 2016-12-31 | $5.41B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $13.13B derived: sum of 2 quarters · filed 2018-02-13 | $19.50B derived: sum of 3 quarters · filed 2018-02-13 | $28.09B 10-K · filed 2018-02-13 |
| 2016-09-30 | $7.71B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $14.09B derived: sum of 2 quarters · filed 2017-10-26 | $22.68B 10-Q · filed 2017-10-26 | $28.87B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $6.37B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-26 | $14.97B 10-Q · filed 2017-07-26 | $21.15B derived: sum of 3 quarters · filed 2018-02-13 | $27.42B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $8.60B 10-Q · filed 2017-04-27 | $14.78B derived: sum of 2 quarters · filed 2018-02-13 | $21.04B derived: sum of 3 quarters · filed 2018-02-13 | $27.64B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $6.18B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $12.45B derived: sum of 2 quarters · filed 2018-02-13 | $19.05B derived: sum of 3 quarters · filed 2018-02-13 | $25.98B 10-K · filed 2018-02-13 |
| 2015-09-30 | $6.26B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28 | $12.86B derived: sum of 2 quarters · filed 2016-10-28 | $19.79B 10-Q · filed 2016-10-28 | $24.84B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $6.60B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-29 | $13.53B 10-Q · filed 2016-07-29 | $18.58B derived: sum of 3 quarters · filed 2017-02-14 | $23.82B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $6.93B 10-Q · filed 2016-05-02 | $11.98B derived: sum of 2 quarters · filed 2017-02-14 | $17.22B derived: sum of 3 quarters · filed 2017-02-14 | $29.93B derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $5.05B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $10.29B derived: sum of 2 quarters · filed 2017-02-14 | $22.99B derived: sum of 3 quarters · filed 2017-02-14 | $25.88B 10-K · filed 2017-02-14 |
| 2014-09-30 | $5.24B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $17.95B derived: sum of 2 quarters · filed 2015-11-02 | $20.83B 10-Q · filed 2015-11-02 | $24.92B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $12.71B derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $15.59B 10-Q · filed 2015-08-05 | $19.68B derived: sum of 3 quarters · filed 2016-10-31 | $26.78B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $2.88B 10-Q · filed 2015-04-27 | $6.97B derived: sum of 2 quarters · filed 2016-10-31 | $14.07B derived: sum of 3 quarters · filed 2016-10-31 | $17.89B derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | $4.09B derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | $11.19B derived: sum of 2 quarters · filed 2016-10-31 | $15.00B derived: sum of 3 quarters · filed 2016-10-31 | $21.96B 8-K · filed 2016-10-31 |
| 2013-09-30 | $7.10B derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | $10.91B derived: sum of 2 quarters · filed 2014-10-29 | $17.88B 10-Q · filed 2014-10-29 | $25.25B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $3.81B derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $10.77B 10-Q · filed 2014-08-05 | $18.15B derived: sum of 3 quarters · filed 2015-02-19 | $24.78B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $6.96B 10-Q · filed 2014-04-30 | $14.34B derived: sum of 2 quarters · filed 2015-02-19 | $20.97B derived: sum of 3 quarters · filed 2015-02-19 | $27.07B derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $7.38B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $14.01B derived: sum of 2 quarters · filed 2015-02-19 | $20.11B derived: sum of 3 quarters · filed 2015-02-19 | $26.24B 10-K · filed 2015-02-19 |
| 2012-09-30 | $6.63B derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $12.73B derived: sum of 2 quarters · filed 2013-10-29 | $18.86B 10-Q · filed 2013-10-29 | $21.57B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $6.10B derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $12.23B 10-Q · filed 2013-08-06 | $14.94B derived: sum of 3 quarters · filed 2014-02-24 | $20.21B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | $6.13B 10-Q · filed 2013-05-03 | $8.84B derived: sum of 2 quarters · filed 2014-02-24 | $14.11B derived: sum of 3 quarters · filed 2014-02-24 | $20.11B derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $2.70B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $7.98B derived: sum of 2 quarters · filed 2014-02-24 | $13.98B derived: sum of 3 quarters · filed 2014-02-24 | $21.18B 10-K · filed 2014-02-24 |
| 2011-09-30 | $5.27B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $11.28B derived: sum of 2 quarters · filed 2012-11-06 | $18.48B 10-Q · filed 2012-11-06 | $21.46B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $6.00B derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $13.21B 10-Q · filed 2012-08-08 | $16.19B derived: sum of 3 quarters · filed 2013-02-27 | $20.20B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $7.20B 10-Q · filed 2012-05-08 | $10.19B derived: sum of 2 quarters · filed 2013-02-27 | $14.20B derived: sum of 3 quarters · filed 2013-02-27 | $18.64B derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $2.98B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $7.00B derived: sum of 2 quarters · filed 2013-02-27 | $11.44B derived: sum of 3 quarters · filed 2013-02-27 | $14.60B 10-K · filed 2013-02-27 |
| 2010-09-30 | $4.01B derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $8.46B derived: sum of 2 quarters · filed 2011-11-04 | $11.62B 10-Q · filed 2011-11-04 | $13.15B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $4.45B derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | $7.61B 10-Q · filed 2011-08-08 | $9.14B derived: sum of 3 quarters · filed 2012-02-29 | $12.54B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $3.16B 10-Q · filed 2011-05-10 | $4.69B derived: sum of 2 quarters · filed 2012-02-29 | $8.10B derived: sum of 3 quarters · filed 2012-02-29 | $12.00B derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $1.53B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $4.93B derived: sum of 2 quarters · filed 2012-02-29 | $8.84B derived: sum of 3 quarters · filed 2012-02-29 | $12.42B 10-K · filed 2012-02-29 |
| 2009-09-30 | $3.41B derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $7.31B derived: sum of 2 quarters · filed 2010-11-08 | $10.89B 10-Q · filed 2010-11-08 | $13.44B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-06-30 | $3.90B derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | $7.48B 10-Q · filed 2010-08-09 | $10.03B derived: sum of 3 quarters · filed 2011-02-25 | $14.41B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-03-31 | $3.58B 10-Q · filed 2010-05-07 | $6.13B derived: sum of 2 quarters · filed 2011-02-25 | $10.50B derived: sum of 3 quarters · filed 2011-02-25 | |
| 2008-12-31 | $2.55B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $6.92B derived: sum of 2 quarters · filed 2011-02-25 | $10.35B 10-K · filed 2011-02-25 | |
| 2008-09-30 | $4.37B derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-06 | $7.79B 10-Q · filed 2009-11-06 | ||
| 2008-06-30 | $3.42B 10-Q · filed 2009-08-10 | |||
| 2007-12-31 | $5.58B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |